XML Financial LLC Has $170,000 Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

XML Financial LLC lifted its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 58.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,000 shares of the biotechnology company’s stock after purchasing an additional 8,500 shares during the quarter. XML Financial LLC’s holdings in Iovance Biotherapeutics were worth $170,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of IOVA. Perceptive Advisors LLC boosted its holdings in Iovance Biotherapeutics by 34.6% during the second quarter. Perceptive Advisors LLC now owns 25,933,142 shares of the biotechnology company’s stock valued at $207,984,000 after purchasing an additional 6,660,151 shares in the last quarter. Long Focus Capital Management LLC boosted its stake in Iovance Biotherapeutics by 195.1% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,132,000 shares of the biotechnology company’s stock valued at $33,139,000 after buying an additional 2,731,688 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Iovance Biotherapeutics in the fourth quarter valued at $12,927,000. Marshall Wace LLP acquired a new position in Iovance Biotherapeutics during the second quarter worth $12,929,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of Iovance Biotherapeutics by 59.0% during the third quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock valued at $37,872,000 after acquiring an additional 1,496,941 shares during the period. 77.03% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Iovance Biotherapeutics news, Director Ryan D. Maynard sold 50,000 shares of Iovance Biotherapeutics stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $10.06, for a total transaction of $503,000.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $75,450. The trade was a 86.96 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.10% of the company’s stock.

Iovance Biotherapeutics Price Performance

IOVA opened at $6.19 on Friday. The stock has a market capitalization of $1.89 billion, a P/E ratio of -4.15 and a beta of 0.57. The company’s 50 day simple moving average is $7.67 and its 200-day simple moving average is $9.09. Iovance Biotherapeutics, Inc. has a one year low of $5.57 and a one year high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The company had revenue of $58.56 million during the quarter, compared to analysts’ expectations of $53.54 million. During the same period last year, the firm earned ($0.46) EPS. As a group, analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.23 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on IOVA shares. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a report on Wednesday, November 6th. UBS Group started coverage on shares of Iovance Biotherapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $17.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.